Moleculin Biotech (NASDAQ:MBRX) Share Price Crosses Below Fifty Day Moving Average – Here’s What Happened

Moleculin Biotech, Inc. (NASDAQ:MBRX)’s stock price passed below its 50 day moving average during trading on Friday . The stock has a 50 day moving average of $2.55 and traded as low as $2.05. Moleculin Biotech shares last traded at $2.10, with a volume of 152,089 shares trading hands.

Analyst Ratings Changes

A number of equities analysts have weighed in on the company. Weiss Ratings restated a “sell (e+)” rating on shares of Moleculin Biotech in a report on Tuesday, April 21st. Wall Street Zen cut shares of Moleculin Biotech from a “sell” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright reissued a “buy” rating and set a $22.00 target price on shares of Moleculin Biotech in a research report on Tuesday, March 24th. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $22.00.

Moleculin Biotech Trading Down 3.2%

The business has a 50 day simple moving average of $2.55 and a two-hundred day simple moving average of $2.90. The stock has a market cap of $11.21 million, a price-to-earnings ratio of -0.12 and a beta of 1.75.

Moleculin Biotech (NASDAQ:MBRX) last released its earnings results on Thursday, May 14th. The company reported ($3.54) EPS for the quarter, missing the consensus estimate of ($2.33) by ($1.21). Research analysts anticipate that Moleculin Biotech, Inc. will post -5.1 EPS for the current fiscal year.

Hedge Funds Weigh In On Moleculin Biotech

A hedge fund recently bought a new position in Moleculin Biotech stock. Jane Street Group LLC acquired a new stake in shares of Moleculin Biotech, Inc. (NASDAQ:MBRX) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 22,550 shares of the company’s stock, valued at approximately $75,000. Jane Street Group LLC owned approximately 1.11% of Moleculin Biotech as of its most recent SEC filing. Hedge funds and other institutional investors own 15.52% of the company’s stock.

About Moleculin Biotech

Moleculin Biotech, Inc is a clinical-stage pharmaceutical company focused on the development of novel therapies for the treatment of highly resistant tumors and viral infections. The company’s research platform centers on the design and synthesis of drug candidates that target key cellular pathways in cancer cells and viral replication processes. By leveraging a proprietary chemistry approach, Moleculin aims to address diseases that have limited therapeutic options and high unmet medical need.

The company’s pipeline includes multiple product candidates at various stages of development.